Twist Bioscience Corp (TWST) shareholders
Close on Nov 17, 2026Market cap $7.02BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (14.40%) | 9,535,193 | 14.40% | 13G (passive) amendment | Sep 30, 2026 |
| Artisan Partners Holdings LP Joint filing with Artisan Partners Asset Management Inc. (10.60%), Artisan Investments GP LLC (10.60%) and 1 more | 6,410,900 | 10.60% | 13G (passive) amendment | Sep 30, 2025 |
| Artisan Partners Limited Partnership Joint filing with Artisan Partners Asset Management Inc. (10.10%), Artisan Partners Holdings LP (10.10%) and 1 more | 6,217,213 | 10.10% | 13G (passive) amendment | Feb 27, 2026 |
| Artisan Investments GP LLC Joint filing with Artisan Partners Asset Management Inc. (9.50%), Artisan Partners Holdings LP (9.50%) and 1 more | 5,830,205 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 4,927,750 | 8.30% | 13G (passive) amendment | Mar 31, 2025 |
| Artisan Partners Asset Management Inc. Joint filing with Artisan Partners Holdings LP (7.70%), Artisan Investments GP LLC (7.70%) and 1 more | 4,802,017 | 7.70% | 13G (passive) amendment | Jun 30, 2026 |
| T. Rowe Price Associates, Inc. | 3,634,470 | 5.80% | 13G (passive) | Jun 30, 2026 |
| ARK Investment Management LLC Joint filing with Catherine D. Wood (5.11%) | 3,385,850 | 5.11% | 13G (passive) amendment | Aug 31, 2026 |
| Vanguard Capital Management | 3,101,909 | 5.05% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TWST | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,833,891 | 9.30% | $600.19M | +279,529 | 0.01% |
| Artisan Partners Limited Partnership | 4,802,017 | 7.66% | $494.03M | −1,565,760 | 0.78% |
| FMR LLC | 4,703,044 | 7.50% | $483.85M | +2,813,099 | 0.02% |
| ARK Investment Management LLC | 4,549,803 | 7.26% | $468.08M | −1,792,930 | 3.04% |
| Price T Rowe Associates Inc /Md/ | 3,634,652 | 5.80% | $373.93M | +3,564,347 | 0.04% |
| State Street Corp | 3,232,532 | 5.15% | $332.56M | −438,150 | 0.01% |
| Vanguard Portfolio Management LLC | 2,824,989 | 4.51% | $290.63M | +175,888 | 0.01% |
| Vanguard Capital Management LLC | 2,699,280 | 4.30% | $277.70M | +60,236 | 0.01% |
| EdgePoint Investment Group Inc. | 2,521,635 | 4.02% | $259.43M | −2,860,886 | 1.96% |
| William Blair Investment Management, LLC | 2,174,594 | 3.47% | $223.72M | −3,095,124 | 0.67% |
| Farallon Capital Management LLC | 2,136,400 | 3.41% | $219.79M | +708,750 | 1.01% |
| Invesco Ltd. | 1,928,229 | 3.07% | $198.38M | −243,669 | 0.02% |
| Geode Capital Management, LLC | 1,619,361 | 2.58% | $166.63M | +99,648 | 0.01% |
| Thrivent Financial for Lutherans | 1,433,503 | 2.29% | $147.48M | +120,959 | 0.25% |
| Goldman Sachs Group Inc | 1,408,418 | 2.25% | $144.90M | −297,128 | 0.01% |
| Morgan Stanley | 1,189,861 | 1.90% | $122.41M | +643,016 | 0.01% |
| D. E. Shaw & Co., Inc. | 1,185,605 | 1.89% | $121.98M | +1,138,961 | 0.06% |
| Baillie Gifford & Co | 1,086,779 | 1.73% | $111.81M | −128,372 | 0.10% |
| Driehaus Capital Management LLC | 1,022,526 | 1.63% | $105.20M | +437,830 | 0.61% |
| Sumitomo Mitsui Trust Holdings, Inc. | 1,000,344 | 1.60% | $102.92M | −495,755 | 0.06% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 336 | 76M | 100.0% | 90 / 100 | 101 / 31 | 19M | 20M |
| Q1 2026 | 281 | 77M | 100.0% | 70 / 76 | 89 / 27 | 18M | 10M |
| Q4 2025 | 244 | 75M | 100.0% | 48 / 75 | 77 / 38 | 9M | 9M |
| Q3 2025 | 239 | 75M | 100.0% | 34 / 98 | 63 / 35 | 11M | 8M |
| Q2 2025 | 244 | 71M | 100.0% | 35 / 80 | 89 / 51 | 9M | 8M |
| Q1 2025 | 263 | 70M | 100.0% | 47 / 91 | 79 / 26 | 9M | 5M |
| Q4 2024 | 247 | 66M | 100.0% | 32 / 89 | 84 / 28 | 6M | 8M |
| Q3 2024 | 246 | 69M | 100.0% | 35 / 91 | 77 / 50 | 12M | 7M |
| Q2 2024 | 263 | 69M | 100.0% | 62 / 88 | 79 / 35 | 10M | 12M |
| Q1 2024 | 238 | 73M | 100.0% | 44 / 79 | 75 / 24 | 6M | 6M |
| Q4 2023 | 219 | 73M | 100.0% | 46 / 57 | 74 / 20 | 13M | 6M |
| Q3 2023 | 195 | 66M | 100.0% | 28 / 57 | 66 / 26 | 5M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
327 funds held TWST in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TWST | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Innovation ETF | 2,010,667 | 3.21% | $184.08M | 3.31% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,874,473 | 2.99% | $192.85M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,594,038 | 2.54% | $163.99M | 0.20% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,469,111 | 2.34% | $151.14M | 1.41% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,357,205 | 2.16% | $139.63M | 0.07% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 1,314,736 | 2.10% | $120.36M | 7.73% | Jul 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 959,300 | 1.53% | $98.69M | 0.67% | Jun 30, 2026 |
| Artisan Mid Cap Fund | 893,167 | 1.42% | $91.89M | 2.88% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 866,923 | 1.38% | $89.19M | 0.80% | Jun 30, 2026 |
| Invesco Discovery Fund | 822,247 | 1.31% | $54.98M | 0.70% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 780,792 | 1.25% | $80.33M | 0.17% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 714,822 | 1.14% | $73.54M | 0.08% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 679,049 | 1.08% | $62.17M | 0.18% | Jul 31, 2026 |
| Vanguard Explorer Fund | 604,500 | 0.96% | $55.34M | 0.25% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 573,272 | 0.91% | $58.98M | 0.38% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Emily M. Leproust | Chief Executive Officer, Director | 656,044 | 1.05% | Nov 16, 2026 |
| Patrick John Finn | President and COO | 233,913 | 0.37% | Nov 16, 2026 |
| Paula Green | SVP of Human Resources | 126,054 | 0.20% | Nov 16, 2026 |
| Adam Laponis | Chief Financial Officer | 124,860 | 0.20% | Nov 16, 2026 |
| Dennis Cho | See Remarks | 85,665 | 0.14% | Nov 16, 2026 |
| Robert F. Werner | Chief Accounting Officer | 51,208 | 0.08% | Nov 16, 2026 |
| Katryn Blake | Director | 17,208 | 0.03% | Aug 14, 2026 |
| Robert Chess | Director | 63,612 | 0.10% | Aug 11, 2026 |
| Melissa A. Starovasnik | Director | 22,222 | 0.04% | Jun 1, 2026 |
| Jan Johannessen | Director | 29,754 | 0.05% | May 14, 2026 |
| Keith Crandell | Director | 103,618 | 0.17% | Feb 9, 2026 |
| Robert P. Ragusa | Director | 28,983 | 0.05% | Feb 9, 2026 |
| Nelson Chan | Director | 33,251 | 0.05% | Feb 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dennis Cho See Remarks | Nov 12, 2026 | Award | +22,825 | – | – | 85,665 |
| Emily M. Leproust Chief Executive Officer, Director | Nov 12, 2026 | Award | +95,351 | – | – | 653,538 |
| Patrick John Finn President and COO | Nov 12, 2026 | Award | +53,635 | – | – | 233,913 |
| Adam Laponis Chief Financial Officer | Nov 12, 2026 | Award | +26,746 | – | – | 124,860 |
| Paula Green SVP of Human Resources | Nov 12, 2026 | Sale | +20,429 | – | – | 126,054 |
| Robert F. Werner Chief Accounting Officer | Nov 12, 2026 | Award | +8,439 | – | – | 51,208 |
| Dennis Cho See Remarks | Nov 3, 2026 | Sale | −949 | $135.40 | $128.50K | 62,840 |
| Patrick John Finn President and COO | Nov 3, 2026 | Sale | −2,565 | $135.40 | $347.31K | 180,278 |
| Paula Green SVP of Human Resources | Nov 3, 2026 | Sale | −1,007 | $135.40 | $136.35K | 105,625 |
| Emily M. Leproust Chief Executive Officer, Director | Nov 3, 2026 | Sale | −4,573 | $135.40 | $619.19K | 558,187 |
| Robert F. Werner Chief Accounting Officer | Nov 3, 2026 | Sale | −148 | $135.40 | $20.04K | 42,769 |
| Patrick John Finn President and COO | Oct 23, 2026 | Sale | −2,245 | $134.59 | $302.15K | 182,843 |
| Adam Laponis Chief Financial Officer | Oct 9, 2026 | Sale | −2,462 | $156.30 | $384.82K | 98,114 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −45 | $207.46 | $9.34K | 562,760 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −146 | $206.84 | $30.20K | 562,805 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −297 | $205.78 | $61.12K | 562,951 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −290 | $204.80 | $59.39K | 563,248 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −432 | $203.61 | $87.96K | 563,538 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −1,017 | $202.32 | $205.76K | 563,970 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −481 | $201.26 | $96.80K | 564,987 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 5, 2026 | Sale(10b5-1 plan) | −1,840 | $200.44 | $368.81K | 565,468 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 2, 2026 | Sale(10b5-1 plan) | −45,736 | $188.88 | $8.64M | 567,308 |
| Robert F. Werner Chief Accounting Officer | Oct 2, 2026 | Sale | −1,482 | $188.88 | $279.93K | 42,917 |
| Adam Laponis Chief Financial Officer | Oct 2, 2026 | Sale | −8,057 | $188.88 | $1.52M | 100,576 |
| Paula Green SVP of Human Resources | Oct 2, 2026 | Sale | −10,088 | $188.88 | $1.91M | 106,632 |
| Patrick John Finn President and COO | Oct 2, 2026 | Sale | −25,714 | $188.88 | $4.86M | 185,088 |
| Dennis Cho See Remarks | Oct 2, 2026 | Sale | −9,514 | $188.88 | $1.80M | 63,789 |
| Emily M. Leproust Chief Executive Officer, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −655 | $200.00 | $131.00K | 613,044 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −83 | $184.60 | $15.32K | 613,699 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −2,485 | $175.23 | $435.45K | 616,417 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −945 | $176.39 | $166.69K | 615,472 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −164 | $177.17 | $29.06K | 615,308 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −330 | $178.67 | $58.96K | 614,978 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −143 | $179.93 | $25.73K | 614,835 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −515 | $180.39 | $92.90K | 614,320 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −21 | $181.45 | $3.81K | 614,299 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −501 | $183.76 | $92.06K | 613,782 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −16 | $182.50 | $2.92K | 614,283 |
| Paula Green SVP of Human Resources | Sep 21, 2026 | Sale | −294 | $165.49 | $48.65K | 116,720 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 21, 2026 | Sale | −1,687 | $165.49 | $279.18K | 618,902 |
| Dennis Cho See Remarks | Sep 21, 2026 | Sale | −348 | $165.49 | $57.59K | 73,303 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −14,493 | $160.44 | $2.33M | 635,192 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −23,884 | $159.53 | $3.81M | 649,685 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −232,173 | $158.09 | $36.70M | 673,569 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −32,260 | $157.49 | $5.08M | 905,742 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −9,097 | $156.47 | $1.42M | 938,002 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −13,378 | $155.46 | $2.08M | 947,099 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −869 | $163.39 | $141.99K | 620,589 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −3,399 | $153.40 | $521.41K | 964,652 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −6,644 | $152.21 | $1.01M | 968,051 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −2,440 | $151.46 | $369.56K | 974,695 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Option exercise | +75,439 | $8.82 | $665.37K | 977,135 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Option exercise | +133,269 | $26.66 | $3.55M | 901,696 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −11,169 | $161.49 | $1.80M | 624,023 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −2,565 | $162.31 | $416.33K | 621,458 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −4,175 | $154.17 | $643.66K | 960,477 |
| Paula Green SVP of Human Resources | Sep 8, 2026 | Sale | −907 | $122.62 | $111.22K | 117,014 |
| Robert F. Werner Chief Accounting Officer | Sep 8, 2026 | Sale | −238 | $122.62 | $29.18K | 44,399 |
| Dennis Cho See Remarks | Sep 8, 2026 | Sale | −412 | $122.62 | $50.52K | 73,651 |
| Emily M. Leproust Chief Executive Officer, Director | Sep 8, 2026 | Sale | −2,302 | $122.62 | $282.27K | 768,427 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Twist Bioscience's stock actually held short. Settlement fails (shares not delivered on time) peaked at 13,965 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Robert F. Werner Officer | Nov 3, 2026 | 148 | $20.04K | Nov 3, 2026 | Restricted Stock Vesting |
| Patrick John Finn Officer | Nov 3, 2026 | 2,565 | $347.31K | Nov 3, 2026 | Restricted Stock Vesting |
| Dennis Cho Officer | Nov 3, 2026 | 949 | $128.50K | Nov 3, 2026 | Restricted Stock Vesting |
| Emily M. Leproust Officer, Director | Nov 3, 2026 | 4,573 | $619.19K | Nov 3, 2026 | Restricted Stock Vesting |
| Paula Green Officer | Nov 3, 2026 | 1,007 | $136.35K | Nov 3, 2026 | Restricted Stock Vesting |
| Patrick John Finn Officer | Oct 23, 2026 | 2,245 | $302.15K | Oct 23, 2026 | Restricted Stock Vesting |
| Adam Laponis Officer | Oct 9, 2026 | 2,462 | $384.82K | Oct 9, 2026 | Restricted Stock Vesting |
| Emily M. Leproust Officer, Director | Oct 5, 2026 | 4,548 | $919.37K | Oct 5, 2026 | Restricted Stock Vesting |
| Patrick John Finn Officer | Oct 2, 2026 | 25,714 | $4.86M | Oct 2, 2026 | Restricted Stock Vesting |
| Adam Laponis Officer | Oct 2, 2026 | 8,057 | $1.52M | Oct 2, 2026 | Restricted Stock Vesting |
| Emily M. Leproust Officer, Director | Oct 2, 2026 | 45,736 | $8.64M | Oct 2, 2026 | Restricted Stock Vesting |
| Dennis Cho Officer | Oct 2, 2026 | 9,514 | $1.80M | Oct 2, 2026 | Restricted Stock Vesting |
| Robert F. Werner Officer | Oct 2, 2026 | 1,482 | $279.93K | Oct 2, 2026 | Restricted Stock Vesting |
| Paula Green Officer | Oct 2, 2026 | 10,088 | $1.91M | Oct 2, 2026 | Restricted Stock Vesting |
| Emily M. Leproust Officer, Director | Oct 1, 2026 | 655 | $131.00K | Oct 1, 2026 | Restricted Stock Vesting |
Congress trades
1 trade in Twist Bioscience reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Dwight Evans PA03 | Sold | Mar 30, 2022 | $1K–15K | Apr 25, 2022 |
See a number that looks wrong?